Is tirzepatide FSA eligible? Often, yes, when a licensed provider prescribes it to treat a diagnosed condition such as obesity. IRS Publication 502 counts prescribed drugs and weight-loss treatment for a disease diagnosed by a physician. The same rule covers semaglutide and HSAs. Your plan administrator decides each claim, so documentation matters.
Written by Kiara DeWitt, BSN, RN, CPN, Founder and CEO of InjectCo
Medically reviewed by Dr. Josh Allen, D.O., Medical Director, October 23, 2026
Disclaimer: This article is general education, not medical, tax or financial advice, and results of any weight loss treatment vary. Compounded medications are not FDA-approved, and your plan administrator decides what it reimburses.
HSA and FSA eligibility follows the IRS definition of a medical expense in Publication 502. Two parts of it matter here.
First, medicines. Publication 502 lets you include amounts you pay for prescribed medicines and drugs, and it defines a prescribed drug as one that needs a doctor’s prescription. Tirzepatide and semaglutide are prescription-only injections. MedlinePlus lists tirzepatide for blood sugar control in type 2 diabetes, for obstructive sleep apnea in adults with obesity, and for weight loss in people who have obesity or overweight with weight-related medical problems. Semaglutide has a similar list.
Second, weight loss. Publication 502 lets you include amounts you pay to lose weight when it is treatment for a specific disease diagnosed by a physician, such as obesity, hypertension or heart disease. It excludes weight loss whose purpose is appearance, general health or a sense of well-being.
So the question your plan asks is not “which drug is this?” It is “why was it prescribed, and is that reason on record?”
| Question | Short answer |
|---|---|
| Is tirzepatide FSA eligible? | May qualify with a prescription for a diagnosed condition; your plan decides |
| Is semaglutide FSA eligible? | May qualify on the same terms; your plan decides |
| Is tirzepatide HSA eligible? | May qualify under the same Publication 502 standard; you keep the records |
| Do I need a Letter of Medical Necessity? | Sometimes. It depends on your plan |
| Does brand-name vs compounded matter? | Publication 502 looks at the prescription and diagnosis, not the brand. Your plan may set its own rules |
Claims are easiest to support when your record names a specific condition, for example:
The same prescription can be approved for one person and denied for another. Often the difference is the chart. “Weight management” on its own can read like a wellness expense. A record that names the diagnosis, the related conditions and the treatment purpose reads like medical care.
Both accounts use the same IRS definition of a medical expense. They differ in who checks the claim.
An HSA is your own account. You decide whether a withdrawal is for a qualified medical expense, and IRS Publication 969 says you must keep records showing that it was. Nobody approves the withdrawal up front, but the IRS can ask later, so save the prescription and the receipt.
A health FSA runs through your employer’s plan administrator. The administrator reviews each claim before it pays and can ask for a receipt, the prescription or a Letter of Medical Necessity. HealthEquity, a plan administrator, says a prescription is essential for GLP-1 medications to meet IRS rules and that FSA claims are reviewed before reimbursement. Check your own plan’s GLP-1 rules before you pay.
Qualifying is step one. These five steps help your diagnosis, prescription and payment records all tell the same story.
Your provider reviews your health history, weight, current conditions, medications and anything that would make a GLP-1 a poor fit. That visit starts the paper trail your administrator may want to see. It is fair to ask, “Can you record my diagnosis and the medical reason for this prescription?” Asking upfront can save a follow-up call later.
The prescription should connect to a documented condition, such as type 2 diabetes, obesity, or overweight with a related condition. Weight loss medications can be reviewed as dual-purpose expenses, so a specific diagnosis is easier to defend than a general goal.
Not every plan requires a Letter of Medical Necessity (LMN), but some do for weight-related prescriptions. An LMN is a signed letter from your provider that usually covers:
Keep a copy. An FSA administrator can ask for it even months after the purchase.
Your card may work at the pharmacy or at your provider’s checkout. Keep the receipt and your paperwork anyway, in case the claim is reviewed later. If the card is declined, that does not always mean the expense is ineligible. Sometimes the payment system does not recognize the merchant. In that case, pay out of pocket and file a claim.
If you paid out of pocket, file through your administrator’s portal. Most ask for an itemized receipt showing what was bought, the date, the provider or pharmacy and the amount. Some also ask for the prescription or an LMN. Keep all three together. Missing documentation is a common reason for denial.
Knowing you may qualify does not help if the paperwork falls short. These are the usual problems and what to do about each.
This is a common failure point. The prescription exists, but it does not name a condition. “Weight management” or “patient requested” gives an administrator room to say no. The fix: ask your provider to record the specific diagnosis, such as obesity, type 2 diabetes or insulin resistance, with its ICD-10 code.
If the visit notes talk about appearance, energy or general wellness and never mention a diagnosis, the claim can fail. A note about slimming down for an event reads as cosmetic. A note that records obesity and the related conditions being treated reads as medical care.
Some FSA administrators require an LMN for weight-related prescriptions no matter the diagnosis. Without it, the claim can fail even when everything else is in order. Call your administrator before you submit and ask whether your plan needs one for GLP-1 medications.
If a merchant is not set up for HSA or FSA cards, the card is declined. That is a payment network issue, not a ruling on eligibility. Pay another way and file a claim with an itemized receipt.
If you use HSA funds for something that is not a qualified medical expense, that amount becomes taxable income. If you are under 65, you also owe an additional 20 percent tax unless an exception, such as disability, applies (IRS Publication 969). Confirm eligibility and keep your records before you pay, not after.
Publication 502 lets you include prescribed medicines, meaning drugs that need a prescription, and it does not list drugs by brand. Compounded tirzepatide and semaglutide are dispensed on a prescription, so under the IRS rule the questions are the same: is there a prescription, a diagnosis and a receipt?
Your plan can still set its own rules. Ask your administrator whether it treats brand-name tirzepatide, brand-name semaglutide and compounded versions the same way. Keep in mind that compounded drugs are not FDA-approved, which means FDA does not review them for safety, effectiveness or quality before they are marketed.
A licensed provider reviews your health history before anything is prescribed, and our program accepts HSA and FSA cards.
$425 a month or $1,800 for a 6 to 8 month program
Some of these surprise people, because they feel like health spending.
Knowing your limits helps you plan a GLP-1 program with pre-tax money.
For 2026, the health FSA contribution limit is $3,400, or about $283 a month. If your plan allows carryover, up to $680 of unused 2026 money can roll into the next plan year (IRS Rev. Proc. 2025-32). For HSAs, you can contribute up to $4,400 for self-only coverage or $8,750 for family coverage with a high-deductible health plan (IRS Rev. Proc. 2025-19). If you are 55 or older, your HSA limit goes up by $1,000 (IRS Publication 969).
To plan your budget, see tirzepatide cost without insurance, semaglutide cost without insurance, or read about paying over time.
Tirzepatide may be FSA eligible when a licensed provider prescribes it to treat a diagnosed condition such as obesity or type 2 diabetes. IRS Publication 502 counts prescribed drugs and weight-loss treatment for a disease diagnosed by a physician. Wanting to lose weight for appearance is not enough. Your FSA administrator reviews each claim and decides, so keep your prescription, diagnosis and itemized receipt ready.
Semaglutide may qualify as an FSA expense when it is prescribed for a diagnosed medical condition. Publication 502 looks at the prescription and the diagnosis, not the brand. Your plan administrator still decides each claim and may ask for an itemized receipt, the prescription or a Letter of Medical Necessity before it pays.
Tirzepatide may be HSA eligible when a licensed provider prescribes it for a diagnosed condition such as obesity, type 2 diabetes, or overweight with a related condition. Nobody approves an HSA withdrawal in advance, but IRS Publication 969 says you must keep records showing the money paid for a qualified medical expense. Save your prescription and itemized receipts.
Not always. Some FSA administrators accept a prescription and an itemized receipt. Others ask for a Letter of Medical Necessity for weight-related prescriptions, even when a diagnosis is on record. Call your administrator before you submit and ask whether your plan requires one for GLP-1 medications. Having one ready can help if your claim is reviewed.
Compounded tirzepatide may qualify under the same IRS standard, because it is dispensed on a prescription for a diagnosed condition, and Publication 502 does not list drugs by brand. Some plans set their own rules for compounded drugs, so check with your administrator first. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness or quality.
Possibly. IRS Publication 502 lets you include amounts paid to lose weight when it is treatment for a specific disease diagnosed by a physician, such as obesity, hypertension or heart disease. Weight loss for appearance or general wellness does not count, and gym dues are excluded. Your plan decides which program fees it reimburses, so ask for an itemized receipt.
The amount becomes taxable income. If you are under 65, you also owe an additional 20 percent tax on top of the income tax, according to IRS Publication 969, unless an exception such as disability applies. That is why it pays to confirm eligibility and keep your records before you spend HSA money on a GLP-1 program.
If you plan to use HSA or FSA money for tirzepatide or semaglutide, the medical reason for treatment should be clear from your first visit.
InjectCo’s tirzepatide weight loss program and compounded semaglutide program are $425 a month or $1,800 for a 6 to 8 month program. Your program includes a consult, labs, medication when prescribed, check-ins every 2 weeks and a monthly dose review, in person or by telehealth. You can pay yourself or with an HSA or FSA card. Ask our team what documentation we can provide for your claim.
Your plan decides what it reimburses. Ask our team what documentation we can provide before you file.
$425 a month or $1,800 for a 6 to 8 month program
Dr. Allen earned his Doctor of Osteopathic Medicine at Lake Erie College of Osteopathic Medicine and completed his emergency medicine residency with Texas A&M. As Medical Director, he reviews InjectCo’s treatments, protocols, and patient education content for accuracy and safety across all nine Texas locations.
